- Home
- MLYS vs PBT Comparison
MLYS vs PBT Comparison
Compare MLYS & PBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- PBT
- Stock Information
- Founded
- MLYS 2019
- PBT 1980
- Country
- MLYS United States
- PBT United States
- Employees
- MLYS N/A
- PBT N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- PBT Oil & Gas Production
- Sector
- MLYS Health Care
- PBT Energy
- Exchange
- MLYS Nasdaq
- PBT Nasdaq
- Market Cap
- MLYS 634.6M
- PBT 599.9M
- IPO Year
- MLYS 2023
- PBT N/A
- Fundamental
- Price
- MLYS $9.50
- PBT $11.67
- Analyst Decision
- MLYS Strong Buy
- PBT
- Analyst Count
- MLYS 2
- PBT 0
- Target Price
- MLYS $30.00
- PBT N/A
- AVG Volume (30 Days)
- MLYS 251.9K
- PBT 198.2K
- Earning Date
- MLYS 11-11-2024
- PBT 01-01-0001
- Dividend Yield
- MLYS N/A
- PBT 4.67%
- EPS Growth
- MLYS N/A
- PBT 25.21
- EPS
- MLYS N/A
- PBT 0.78
- Revenue
- MLYS N/A
- PBT $37,735,284.00
- Revenue This Year
- MLYS N/A
- PBT N/A
- Revenue Next Year
- MLYS N/A
- PBT N/A
- P/E Ratio
- MLYS N/A
- PBT $15.62
- Revenue Growth
- MLYS N/A
- PBT 25.46
- 52 Week Low
- MLYS $7.95
- PBT $10.14
- 52 Week High
- MLYS $16.91
- PBT $15.79
- Technical
- Relative Strength Index (RSI)
- MLYS 33.43
- PBT 48.72
- Support Level
- MLYS $8.60
- PBT $11.48
- Resistance Level
- MLYS $9.97
- PBT $12.24
- Average True Range (ATR)
- MLYS 0.89
- PBT 0.51
- MACD
- MLYS -0.33
- PBT 0.10
- Stochastic Oscillator
- MLYS 18.63
- PBT 71.64
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.